Open Access Open Access  Restricted Access Subscription or Fee Access

Route of administration of exogenous progesterone for luteal support does not significantly affect the serum concentration in assisted reproductive technology

Yangyang Zhang, Yang Xu, Jing Shang, Fei Chen, Yanrong Kuai, Sheng Wang


The objective of this research is to study the guiding role of serum progesterone level on exogenous luteal support protocols. In the retrospective study, a total of 537 infertile women undergoing IVF/ICSI were recruited. Serum samples were obtained for serum progesterone measurements. The results demonstrated that the progesterone levels of all women gradually decreased over the course of 7 days after ET. The progesterone level of the pregnant women reached a nadir on day 7 after ET and subsequently began to rise, while the progesterone level of the non-pregnant women continued to decrease. Even with different routes of administration of exogenous progesterone, the progesterone levels followed the same patterns. The serum progesterone level does not represent the adequacy of exogenous progesterone supplementation. Therefore, there is no need to measure serum progesterone levels frequently after embryo transfer or adjust the dose according to serum progesterone levels. (Afr J Reprod Health 2021; 25[6]: 134-142).

Full Text:



Devoto L, Fuentes A, Kohen P, Cespedes P, Palomino A, Pommer R, Munoz A and Strauss JR. The human corpus luteum: life cycle and function in natural cycles. Fertil Steril, 2009; 92(3):1067-79.

Csapo A I, Pulkkinen M O, Ruttner B, Sauvage JP and Wiest WG. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol, 1972; 112(8):1061-67.

Czyzyk A, Podfigurna A, Genazzani A R and Meczekalski B. The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility. Gynecol Endocrinol, 2017; 33(6):421-4.

Fatemi H M. The luteal phase after 3 decades of IVF: what do we know?. Reprod Biomed Online, 2009; 19 Suppl 4:4331.

Palomba S, Santagni S and La Sala G B. Progesterone administration for luteal phase deficiency in human

reproduction: an old or new issue?. J Ovarian Res, 2015; 8:77.

Pritts E A and Atwood A K. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod, 2002; 17(9):2287-99.

Conforti A, Strina I, Mollo A, Amoroso R, Marrone V, Alviggi C, Marci R and de Placido G. The efficacy of modified luteal phase support with intramuscular progesterone in IVF/ICSI cycles: a retrospective observational study. Eur Rev Med Pharmacol Sci, 2017; 21(4):657-61.

Connell M T, Szatkowski J M, Terry N, DeCherney AH, Propst AM and Hill MJ. Timing luteal support in assisted reproductive technology: a systematic review. Fertil Steril, 2015; 103(4):939-46.

Yanushpolsky E H. Luteal phase support in in vitro fertilization. Semin Reprod Med, 2015; 33(2):118-27.

Propst A M, Hill J A, Ginsburg E S, Hurwitz S, Politch J and Yanushpolsky EH. A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer cycles. Fertil Steril, 2001; 76(6):1144-9.

van der Linden M, Buckingham K, Farquhar C, Kremer JA and Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev, 2015; (7):D9154.

Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C and Hornstein M. Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. Fertil Steril, 2010; 94(7):2596-9.

Tournaye H, Sukhikh G T, Kahler E and Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod, 2017; 32(5):1019-27.

Vaisbuch E, de Ziegler D, Leong M, Weissman A and Shoham Z. Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey. Reprod Biomed Online, 2014; 28(3):330-5.

Mitwally M F, Diamond M P and Abuzeid M. Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo

transfer. Fertil Steril, 2010; 93(2):554-69.

Sonntag B, Loebbecke K C, Nofer J R, Kiesel L and Greb RR. Serum estradiol and progesterone in the mid-luteal phase predict clinical pregnancy outcome in IVF/ICSI cycles. Gynecol Endocrinol, 2013; 29(7):700-3.

Bakas P, Simopoulou M, Giner M, Drakakis P, Panagopoulos P and Vlahos N. Predictive value of repeated measurements of luteal progesterone and estradiol levels in patients with intrauterine insemination and controlled ovarian stimulation. Gynecol Endocrinol, 2017:1-4.

Aslih N, Ellenbogen A, Shavit T, Michaeli M, Yakobi D and Shalom-Paz E. Can we alter pregnancy outcome by adjusting progesterone treatment at mid-luteal phase: a randomized controlled trial. Gynecol Endocrinol, 2017:1-5.


  • There are currently no refbacks.